$Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma$

Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma

Nivolumab, a human immunoglobulin G4-blocking antibody against the T-cell programmed death-1 checkpoint protein, has activity against metastatic melanoma. Its safety, clinical efficacy, and correlative biomarkers were assessed with or without a peptide vaccine in ipilimumab-refractory and -naive mel...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical oncology 2013-12, Vol.31 (34), p.4311-4318
Hauptverfasser:	WEBER, Jeffrey S, RAGINI REINEY KUDCHADKAR, KROEGER, Jodi, EYSMANS, Cabell, SARNAIK, Amod A, ANN CHEN, Y, BIN YU, GALLENSTEIN, Donna, HORAK, Christine E, INZUNZA, H. David, XIUHUA ZHAO, MARTINEZ, Alberto J, WENSHI WANG, GIBNEY, Geoffrey
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Aged, 80 and over Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antineoplastic Agents - therapeutic use Biological and medical sciences Biomarkers, Tumor - blood Cancer Vaccines - adverse effects Cancer Vaccines - therapeutic use Dermatology Disease Progression Disease-Free Survival Female Florida Humans Immunohistochemistry Ipilimumab Male Medical sciences Melanoma - blood Melanoma - drug therapy Melanoma - immunology Melanoma - mortality Melanoma - pathology Middle Aged Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Neoplasm Staging ORIGINAL REPORTS Skin Neoplasms - blood Skin Neoplasms - drug therapy Skin Neoplasms - immunology Skin Neoplasms - mortality Skin Neoplasms - pathology Time Factors Tomography, X-Ray Computed Treatment Failure Tumors Tumors of the skin and soft tissue. Premalignant lesions Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!